Podcasts about life sciences

  • 2,730PODCASTS
  • 6,409EPISODES
  • 32mAVG DURATION
  • 2DAILY NEW EPISODES
  • Jul 9, 2025LATEST
life sciences

POPULARITY

20172018201920202021202220232024





Latest podcast episodes about life sciences

Tiny Matters
Making labs safer: A heavy metal poisoning, a deadly protein exposure, and their aftermath

Tiny Matters

Play Episode Listen Later Jul 9, 2025 35:16


In January, 1997, David Nierenberg was a physician at Dartmouth‐Hitchcock Medical Center, specializing in toxicology. Chemist Karen Wetterhahn was placed in his care. When she arrived at the hospital, Karen was slurring her speech and having difficulty balancing and with coordination. What David soon learned was that her symptoms were all due to a few tiny drops of a compound called dimethylmercury. Today's episode focuses on two lab accidents that had a profound impact on research communities, and that inspired changes that have likely saved the lives of scientists and other workers since. The first story is that of Karen Wetterhahn who, in the 1990s was a professor of chemistry at Dartmouth College whose lab focused on heavy metal toxicity. The other story is about fatal prion protein exposures in France that led to a temporary moratorium in 2021. Send us your science facts, news, or other stories for a chance to be featured on an upcoming Tiny Show and Tell Us bonus episode. And, while you're at it, subscribe to our newsletter!Links to the Tiny Show and Tell stories are here and here. All Tiny Matters transcripts and references are available here.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

MoFo Perspectives Podcast
When Your Life Sciences Are on the Line: IP Litigation and Trials

MoFo Perspectives Podcast

Play Episode Listen Later Jul 9, 2025 21:20


Morrison Foerster partners Kate Driscoll and Nate Mendell, both former federal prosecutors and members of the firm's Investigations + White Collar Defense Group, hosted the tenth episode of When Your Life Sciences Are on the Line, where leading practitioners and thought leaders share the insights and advice needed to manage business and legal risk in the life sciences sector. In this episode, Kate and Nate have a compelling discussion with Daralyn Durie, a partner in Morrison Foerster's Life Sciences and IP Litigation Groups recognized as one of the country's leading trial lawyers. Their conversation delves into the complexities of trial practice within the life sciences sector, highlighting the strategic considerations that drive companies to pursue litigation despite the inherent risks and costs.

Combinate Podcast - Med Device and Pharma
196 - How to Win Your First 90 Days in Pharma and MedTech

Combinate Podcast - Med Device and Pharma

Play Episode Listen Later Jul 9, 2025 9:38


In this episode, I go over 8 lessons to maximize your first 90 days in Life Sciences. These include understanding the impact of their roles, adopting a professional mindset, passing the first 90-day test, avoiding the 'silent trap,' finding mentors, valuing feedback, mastering systems, and taking responsibility for their careers. Subhi emphasizes that these lessons can significantly accelerate growth and career advancement for newcomers to the industry.Link to course: subhisaadeh.gumroad.com/l/6figurebiomedical00:00 Introduction: Starting Your Career Journey00:54 Lesson 1: Your Role Can Have a Big Impact02:55 Lesson 2: Adopting a Professional Mindset04:06 Lesson 3: The First 90 Days Are Crucial05:09 Lesson 4: Avoiding the Silent Trap06:35 Lesson 5: Finding the Right Mentors07:14 Lesson 6: Embrace Feedback as Fuel07:51 Lesson 7: Mastering the Systems08:47 Lesson 8: Taking Responsibility for Your Career09:19 Conclusion and Additional ResourcesSubhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

OffScrip with Matthew Zachary
The Elastic Life of Gigi Robinson

OffScrip with Matthew Zachary

Play Episode Listen Later Jul 8, 2025 46:02


Gigi Robinson grew up with Ehlers-Danlos syndrome, a disease that turns your joints into overcooked spaghetti. Instead of letting it sideline her, she built a career out of telling the truth about invisible illness. We talk about what it takes to grow up faster than you should, why chronic illness is the worst unpaid internship, and how she turned her story into a business. You'll hear about her days schlepping to physical therapy before sunrise, documenting the sterile absurdity of waiting rooms, and finding purpose in the mess. Gigi's not interested in pity or polished narratives. She wants you to see what resilience really looks like, even when it's ugly. If you think you know what an influencer does, think again. This conversation will challenge your assumptions about work, health, and what it means to be seen.RELATED LINKSGigi Robinson Website: https://www.gigirobinson.comLinkedIn: https://www.linkedin.com/in/gigirobinsonInstagram: https://www.instagram.com/itsgigirobinsonTikTok: @itsgigirobinsonA Kids Book About Chronic Illness: https://akidsco.com/products/a-kids-book-about-chronic-illnessFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Workplace Innovator Podcast | Enhancing Your Employee Experience | Facility Management | CRE | Digital Workplace Technology
Ep. 359: “A Better, Positive Outlook” – Life Sciences, Architecture and Workplace Strategy with Dan Castner, AIA, LEED AP of Mancini Duffy

Workplace Innovator Podcast | Enhancing Your Employee Experience | Facility Management | CRE | Digital Workplace Technology

Play Episode Listen Later Jul 8, 2025 21:44


Daniel Castner, AIA, LEED AP is Principal and Director of the Life Science practice at Mancini Duffy where he is passionate about workplace strategy with a focus on research labs, medical space, and anything requiring a helpful orchestrator of AEC coordination. Mike Petrusky asks Dan about his experiences helping the IFMA community, the importance of client relationships and the use of technology in workplace strategy. They explore design trends and emphasize the core elements of flexibility and being intentional when delivering spaces that meet the needs of the workforce. Dan believes that change management has evolved to focus more on the employee experience and wellbeing, rather than just specific projects, so using sensors and analytics can help leaders understand human priorities. Dan's unique experience in life science workplaces have led him to focus on building a culture of collaboration and innovation, so he shares some encouragement, practical advice and the inspiration you will need to be a Workplace Innovator! Take the Eptura™ Podcast Survey: https://forms.office.com/r/jY577CbNcx Connect with Dan on LinkedIn: https://www.linkedin.com/in/danielcastner/ Learn more about Mancini Duffy: https://www.manciniduffy.com/ Discover free resources and explore past interviews at: https://www.workplaceinnovator.com/ Learn more about Eptura™: https://eptura.com/ Connect with Mike on LinkedIn: https://www.linkedin.com/in/mikepetrusky/  

The Synopsis
Interview. Precision Medicine Fund Manager on Portfolio Construction, Risk, and "Developers" vs "Enablers"

The Synopsis

Play Episode Listen Later Jul 8, 2025 75:59


In this insightful interview with Blue Box Asset Mangement's Porfolio Manager Mark Dainty we talk about precision medicine and life sciences, his investment strategy, and how he constructs a portfolio of "developers" vs "enablers". We also talk about 3 stocks in the fund. We hope you enjoy listening!  *~*~*~*~*  Get access to all of Speedwell Research's in-depth Research Reports here. If you need help getting Speedwell added as an approved research vendor for your investment firm, please reach out to info@speedwellresearch.com  -*-*-*-*-*-*-*-*-*-*- Show Notes (0:00) — What is Precision Medicine and Life Sciences (11:15) — Small Markets, but Higher Prices (22:24) — Why Precision Medicine is like Dating Apps (27:56) — Investment Strategy and Portfolio Construction (47:20) — Two Stocks: Natera ($NTRA) and Guardant Health ($GH) (54:24) — Risk of the Unknown? (1:02:55) — Revolutions Medicines ($RVMD) (1:11:10) — Financial Modeling -*-*-*-*-*-*-*-*-*-*- Become a Speedwell Member here to gain access to *all* of our in-depth research reports and more!   Sign up for Speedwell's free newsletter and weekly memos here *~*~*~*~*  Follow Us: Twitter: @Speedwell_LLC Threads: @speedwell_research Email us at info@speedwellresearch.com for any questions, comments, or feedback. -*-*-*-*-*-*-*-*-*-*- Disclaimer Nothing in this podcast is investment advice nor should be construed as such. Contributors to the podcast may own securities discussed. Furthermore, accounts contributors advise on may also have positions in companies discussed. Please see our full disclaimers here:  https://speedwellresearch.com/disclaimer/

Audio podcast of the Interpreter Foundation
Reconciling Evolution by Faith or Framing?

Audio podcast of the Interpreter Foundation

Play Episode Listen Later Jul 4, 2025 16:33


Review of Jamie L. Jensen, Steven L. Peck, Ugo A. Perego, and T. Benjamin Spackman, eds. The Restored Gospel of Jesus Christ and Evolution. Provo, UT: College of Life Sciences, Brigham Young University, 2025. 272 pgs. Abstract: This review critically evaluates The Restored Gospel of Jesus Christ and Evolution, a multi-author volume that seeks to harmonize […] The post Reconciling Evolution by Faith or Framing? first appeared on The Interpreter Foundation.

Psych Health and Safety Podcast USA
Psychological Health, Safety, and My Rights with Gloria Hartley

Psych Health and Safety Podcast USA

Play Episode Listen Later Jul 4, 2025 51:28


Dive into Episode #148 of the Psych Health and Safety USA Podcast, featuring host Dr. I. David Daniels, PhD, CSD, VPS, and special guest Gloria Hartley, the Civil Rights Compliance Coordinator at the College of Agriculture and Life Sciences at Virginia Tech University. She is also the child of immigrants, a veteran of the United States Navy, and has spent over a decade in and around the human resource space in both the private and public sectors. One of her professional goals has been to convert conversations about Civil and Human Rights into practical language and steps that people can take to protect workers and the organization. Civil rights and psychosocial safety are deeply interconnected. Civil rights ensure that individuals are protected from discrimination and have equal access to opportunities, which is fundamental for creating a safe and inclusive environment. Psychosocial safety, however, refers to the psychological and social conditions that allow individuals to feel safe, respected, and valued in their communities and workplaces. Individuals are more likely to experience psychosocial safety when civil rights are upheld because they are protected from discrimination, harassment, and other forms of harm. This creates an environment where people can express themselves freely, participate fully in society, and feel a sense of belonging. Conversely, when civil rights are violated, it can lead to a lack of psychosocial safety, resulting in stress, anxiety, and other adverse mental health outcomes. LinkedIn Profile https://www.linkedin.com/in/gloriamhartley/

Tiny Matters
[BONUS] Fetuses ‘listening' to different languages and climate change affecting psychiatric meds: Tiny Show and Tell Us #26

Tiny Matters

Play Episode Listen Later Jul 2, 2025 15:55


In this episode of Tiny Show and Tell Us, we talk about how climate change may impact the effectiveness of mental health medications and how heat waves impact mental health more generally. Then we cover how fetal heart rates can change depending on which language they're hearing while in the womb. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Emily Chang’s Tech Briefing
The pistachio industry is growing - thanks in part to Dubai chocolate

Emily Chang’s Tech Briefing

Play Episode Listen Later Jul 2, 2025 3:45


This is the daily Tech and Business Report. Today, KCBS Radio anchor Holly Quan spoke with Bloomberg's Ilena Peng. Pistachio farmers in California are having a great year, thanks in part to a chocolate shop in the United Arab Emirates.

BioSpace
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP

BioSpace

Play Episode Listen Later Jul 2, 2025 23:48


The U.S. Supreme Court closed out its session before breaking for summer on Friday, ruling that decisions around coverage of HIV PrEP drugs should be left up to the U.S. Preventive Services Task Force. The ruling thwarted a lawsuit brought by a group of insurance providers who challenged the Affordable Care Act's requirement that they cover preventive medicines, such as HIV drugs, recommended by the task force. The high court also determined that members of this task force can be removed at will by HHS Secretary Robert F. Kennedy Jr.Speaking of HHS committees from which members have been removed at will by Kennedy, the CDC's revamped Advisory Committee on Immunization Practices convened last week for its first meeting since the roster overhaul, where a vote on Merck's recently approved RSV-targeting monoclonal antibody Enflonsia and a discussion around the inclusion of preservative thimerosal in influenza vaccines was on the docket, but an expected vote on Moderna's mRNA-based RSV shot mRESVIA was not.Also dominating the headlines on Friday was the FDA's decision to remove the Risk Evaluation and Mitigation Strategies (REMS) program from the six approved CAR T therapies it was applied to. Analysts and patient groups lauded the move, which is expected to potentially double access to these life-saving therapies, saying it reflects “thoughtful consideration of real-world evidence” and “regulatory trust.”Willliam Blair noted that it could be a “positive signal” to companies developing CAR T therapies for autoimmune diseases, which now includes AbbVie. In an all-cash buyout on Monday, the Illinois-based pharma dropped $1.2 billion for Capstan Therapeutics and its in vivo edited CAR T therapy for B cell–mediated autoimmune diseases. M&A has been on an uptick of late, and private equity companies—such as those that snapped up bluebird bio—are also getting in on the game.Finally, after Lykos Therapeutics' high profile failure last summer, the psychedelics space is heating up once again. While a Phase III readout of Compass Pathways' psilocybin drug last week in treatment-resistant depression received a muted reaction from investors, the response to a Phase II readout for Beckley Psytech and atai Life Sciences' intranasal psychedelic was more positive.

OffScrip with Matthew Zachary
The Bronx Bleeds Blue: Vanessa Ghigliotty vs. Everyone

OffScrip with Matthew Zachary

Play Episode Listen Later Jul 1, 2025 49:41


Episode Description:If you've ever wondered what happens when a Bronx-born pediatric nurse with stage 4 colon cancer survives, raises a kid, becomes a policy shark, and fights like hell for the ignored, meet Vanessa Ghigliotty. She's not inspirational. She's a bulldozer. We go way back—like pre-Stupid Cancer back—when there was no “young adult cancer movement,” just a handful of pissed-off survivors building something out of nothing. This episode is personal. Vanessa and I built the plane while flying it. She fought to be heard, showed up in chemo dragging her kid to IEP meetings, and never stopped screaming for the rest of us to get what we needed. We talk war stories, progress, side-eyeing advocacy fads, TikTok activism, gatekeeping, policy wins, and why being loud is still necessary. And yeah—she's a damn good mom. Probably a better one than you. You'll laugh. You'll cry. You'll want to scream into a pillow. Come for the nostalgia. Stay for the righteous anger and iced coffee.RELATED LINKSVanessa on LinkedInColorectal Cancer Alliance: Vanessa's StoryZenOnco Interview with VanessaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sounds of Science
From Tumor to Treatment: How PDX Models are Powering Cancer Breakthroughs

Sounds of Science

Play Episode Listen Later Jul 1, 2025 19:38


What if a mouse could help shape the future of cancer treatment? In this episode of Sounds of Science, host Mary Parker speaks with Julia Schüler, DVM, PhD, Research Director and Therapeutic Area Lead for Oncology at Charles River. Julia shares how patient-derived xenograft (PDX) models—often described as “avatars” of human tumors—are transforming preclinical oncology research. From preserving tumor heterogeneity to improving translational relevance, PDX models are accelerating the discovery of more effective, personalized therapies. Tune in as we explore how these advanced models are driving innovation across the drug development pipeline—from target discovery to clinical trial design.Show NotesPDX Tumor Organoids : A New Tool in Drug Discovery Testing Realm Organoids: Some Assembly Required Patient-Derived Xenografts- PDX Models 3D Tumor Models In Vitro PDX Assays 

Emily Chang’s Tech Briefing
Trump's proposed research cuts would "set back the US by decades"

Emily Chang’s Tech Briefing

Play Episode Listen Later Jul 1, 2025 4:37


This is the daily Tech and Business Report. Today, KCBS Radio anchor Holly Quan spoke with Bloomberg's Brian K. Sullivan. Big cuts are coming to the National Oceanic and Atmospheric Administration, as the new budget proposal slashes the agency's budget by $1.5 billion. That will result in an estimated 2,200 jobs being cut, which is about 18% of the Administration's workforce.

GZero World with Ian Bremmer
Why life sciences are critical to national security

GZero World with Ian Bremmer

Play Episode Listen Later Jun 30, 2025 30:33


What if the next virus isn't natural, but deliberately engineered and used as a weapon? As geopolitical tensions rise and biological threats become more complex, health security and life sciences are emerging as critical pillars of national defense.In the special edition episode from our new series, “The Ripple Effect: Investing in Life Sciences”, host Dan Riskin is joined by two leading voices at the intersection of biotechnology and defense: Dawn Meyerriecks, former CIA Deputy Director for Science and Technology and current member of the National Security Commission on Emerging Biotechnology, and Jason Kelly, co-founder and CEO of Ginkgo Bioworks. Together, they explore the dual-use nature of biotechnology and the urgent need for international oversight, genetic attribution standards, and robust viral surveillance. From pandemic preparedness and fragile supply chains to AI-driven lab automation and airport biosurveillance, their conversation highlights how life science innovation strengthens national resilience and strategic defense.This timely conversation follows the June 25th, 2025 Hague Summit Declaration, where NATO allies pledged to invest 5% of GDP in defense by 2035—including up to 1.5% on resilience and innovation to safeguard critical infrastructure, civil preparedness, networks, and the defense industrial base. This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Subscribe to “The Ripple Effect: Investing in Life Sciences” series on your preferred podcast platform.Look for the next episode of the GZERO World with Ian Bremmer podcast when we kick off our eighth season on July 5, 2025.Host: Dan RiskinGuests: Jason Kelly, Dawn Meyerriecks Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

John Williams
How McCormick Place reduced bird deaths

John Williams

Play Episode Listen Later Jun 30, 2025


John Bates, Curator and Section Head, Life Sciences, The Field Museum, joins John Williams to talk about the changes made to McCormick Place in Chicago that has kept migrating birds from hitting windows and reducing deaths by 95 percent.

WGN - The John Williams Full Show Podcast
How McCormick Place reduced bird deaths

WGN - The John Williams Full Show Podcast

Play Episode Listen Later Jun 30, 2025


John Bates, Curator and Section Head, Life Sciences, The Field Museum, joins John Williams to talk about the changes made to McCormick Place in Chicago that has kept migrating birds from hitting windows and reducing deaths by 95 percent.

GZERO World with Ian Bremmer
Why life sciences are critical to national security

GZERO World with Ian Bremmer

Play Episode Listen Later Jun 30, 2025 30:33


What if the next virus isn't natural, but deliberately engineered and used as a weapon? As geopolitical tensions rise and biological threats become more complex, health security and life sciences are emerging as critical pillars of national defense.In the special edition episode from our new series, “The Ripple Effect: Investing in Life Sciences”, host Dan Riskin is joined by two leading voices at the intersection of biotechnology and defense: Dawn Meyerriecks, former CIA Deputy Director for Science and Technology and current member of the National Security Commission on Emerging Biotechnology, and Jason Kelly, co-founder and CEO of Ginkgo Bioworks. Together, they explore the dual-use nature of biotechnology and the urgent need for international oversight, genetic attribution standards, and robust viral surveillance. From pandemic preparedness and fragile supply chains to AI-driven lab automation and airport biosurveillance, their conversation highlights how life science innovation strengthens national resilience and strategic defense.This timely conversation follows the June 25th, 2025 Hague Summit Declaration, where NATO allies pledged to invest 5% of GDP in defense by 2035—including up to 1.5% on resilience and innovation to safeguard critical infrastructure, civil preparedness, networks, and the defense industrial base. This limited series, produced by GZERO's Blue Circle Studios in partnership with Novartis, examines how life science innovation plays a vital role in fulfilling that commitment. Subscribe to “The Ripple Effect: Investing in Life Sciences” series on your preferred podcast platform.Look for the next episode of the GZERO World with Ian Bremmer podcast when we kick off our eighth season on July 5, 2025.Host: Dan RiskinGuests: Jason Kelly, Dawn Meyerriecks Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

WGN - The John Williams Uncut Podcast
How McCormick Place reduced bird deaths

WGN - The John Williams Uncut Podcast

Play Episode Listen Later Jun 30, 2025


John Bates, Curator and Section Head, Life Sciences, The Field Museum, joins John Williams to talk about the changes made to McCormick Place in Chicago that has kept migrating birds from hitting windows and reducing deaths by 95 percent.

The Unforget Yourself Show
Propelling Growth through a Cancer Diagnosis with Shannon Gregg

The Unforget Yourself Show

Play Episode Listen Later Jun 26, 2025 34:56


Shannon Gregg is the President of Cloud Adoption Solutions, who helps Life Sciences and Technology companies maximize their Salesforce potential through PhD-backed research in user adoption and change management.Through her expertise in combining people, process, and technology, Shannon guides organizations in regulated industries to unlock sustainable growth while maintaining compliance and driving revenue.Now, Shannon's remarkable journey of completing her PhD, battling stage 3b cancer, and growing her company to a 14-person team demonstrates how determination can fuel success.And while balancing roles as president, professor, and mom, she's even found time to compete on a Mom Jazz dance team and judge international dance competitions, proving that excellence doesn't mean sacrificing joy.Here's where to find more:https://cloudadoption.solutionshttps://shannongregg.comhttps://www.linkedin.com/in/shannonjgregghttps://www.youtube.com/@newtechdemoshttps://www.youtube.com/@shannonj.greggphdmba3314https://thedanceworlds.net/meet-the-judges___________________________________________________________Welcome to The Unforget Yourself Show where we use the power of woo and the proof of science to help you identify your blind spots, and get over your own bullshit so that you can do the fucking thing you ACTUALLY want to do!We're Mark and Katie, the founders of Unforget Yourself and the creators of the Unforget Yourself System and on this podcast, we're here to share REAL conversations about what goes on inside the heart and minds of those brave and crazy enough to start their own business. From the accidental entrepreneur to the laser-focused CEO, we find out how they got to where they are today, not by hearing the go-to story of their success, but talking about how we all have our own BS to deal with and it's through facing ourselves that we find a way to do the fucking thing.Along the way, we hope to show you that YOU are the most important asset in your business (and your life - duh!). Being a business owner is tough! With vulnerability and humor, we get to the real story behind their success and show you that you're not alone._____________________Find all our links to all the things like the socials, how to work with us and how to apply to be on the podcast here: https://linktr.ee/unforgetyourself

The Good Question Podcast
AI Innovations, AGI Challenges, & The Future of Human Interaction: A Conversation with Dr. Bo Wen

The Good Question Podcast

Play Episode Listen Later Jun 26, 2025 46:23


Join us for an enlightening conversation with Dr. Bo Wen, a leading AGI specialist, cloud architect, and staff research scientist at IBM. With expertise in generative AI, human-AI interaction, and computational analysis, Dr. Wen discusses the rapid advancements in AI and their potential impact on the future of human communication and collaboration. Dr. Wen has been instrumental in IBM's Healthcare and Life Sciences division, pioneering AI-driven health solutions, wearables, and IoT technologies. His diverse background spans digital health, cognitive science, computational psychiatry, and physics, giving him a unique perspective on AI's capabilities and risks. In this episode, we explore: Wen's early predictions on AI breakthroughs

Off Script: A Pharma Manufacturing Podcast
Life sciences manufacturers overwhelmingly embrace smart tech: global survey

Off Script: A Pharma Manufacturing Podcast

Play Episode Listen Later Jun 26, 2025 5:00


Smart manufacturing is “nearly universal” with 95% of manufacturers saying they are using or evaluating smart technology, according to a new survey from Rockwell Automation. Greg Slabodkin Read by Brittany Duncan

OffScrip with Matthew Zachary
Ask Better Questions or Die Trying: Risa Arin

OffScrip with Matthew Zachary

Play Episode Listen Later Jun 24, 2025 39:21


Risa Arin doesn't just talk about health literacy. She built the damn platform. As founder and CEO of XpertPatient.com (yes, expert with no E), Risa's taking a wrecking ball to how cancer education is delivered. A Cornell alum, cancer caregiver, and ex-agency insider who once sold Doritos to teens, she now applies that same marketing muscle to helping patients actually understand the garbage fire that is our healthcare system. We talk about why she left the “complacent social safety” of agency life, how her mom unknowingly used her own site during treatment, what it's like to pitch cancer education after someone pitches warm cookies, and why healthcare should come with a map, a translator, and a refund policy. Risa brings data, chutzpah, and Murphy Brown energy to the conversation—and you'll leave smarter, angrier, and maybe even a little more hopeful.RELATED LINKS• XpertPatient.com• Risa Arin on LinkedIn• XpertPatient & Antidote Partnership• XpertPatient Featured on KTLA• 2024 Health Award BioFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Choses à Savoir SANTE
Pourquoi le "paradoxe français" a dopé les ventes de vin ?

Choses à Savoir SANTE

Play Episode Listen Later Jun 23, 2025 3:04


Le "paradoxe français" désigne une observation intrigante : les Français, malgré une alimentation riche en graisses saturées (fromages, beurre, charcuterie), ont un taux relativement bas de maladies cardiovasculaires, en comparaison avec d'autres pays occidentaux comme les États-Unis. Cette contradiction apparente a été mise sous les projecteurs aux États-Unis le 17 novembre 1991, lors d'un épisode de l'émission très populaire 60 Minutes diffusée sur CBS. Le segment, intitulé "The French Paradox", présentait l'idée que la consommation régulière de vin rouge par les Français pourrait être la clé de leur bonne santé cardiovasculaire.L'impact de cette émission a été immédiat : selon les données du Wine Market Council, les ventes de vin rouge ont augmenté de 44 % aux États-Unis dans les mois qui ont suivi. En 1992, le vin rouge représentait environ 70 % des nouvelles ventes de vin sur le marché américain, contre seulement 50 % l'année précédente. Certaines marques françaises comme Château Lafite Rothschild ont vu leur popularité exploser, et les importations de vin français ont fortement progressé.Sur le plan scientifique, l'un des principaux promoteurs de ce concept était le chercheur Serge Renaud de l'INSERM à Lyon. Dans un article publié en 1992 dans The Lancet, il avance que la consommation modérée de vin rouge – un à deux verres par jour – pourrait réduire le risque de maladies coronariennes de 40 %. Le vin rouge contient en effet des polyphénols, dont le plus connu est le resvératrol, un antioxydant présent dans la peau du raisin. Des études comme celle de J.P. Fremont (1999, Life Sciences) ont suggéré que le resvératrol inhibe l'agrégation des plaquettes et protège les vaisseaux sanguins.Le "paradoxe français" est alors devenu un argument marketing massif. L'industrie vinicole, en France comme aux États-Unis, s'en est emparée pour promouvoir le vin rouge comme un produit "santé". Cette stratégie a contribué à modifier l'image du vin outre-Atlantique, le faisant passer d'un produit de luxe européen à un choix de consommation perçu comme bénéfique.Cependant, cette idée a été nuancée depuis. En 2018, une méta-analyse majeure publiée dans The Lancet a conclu qu'aucun niveau de consommation d'alcool n'est totalement sans risque. Malgré cela, l'effet du paradoxe français reste un exemple frappant de la manière dont une hypothèse scientifique, relayée par les médias, peut transformer un marché entier. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Molecule to Market: Inside the outsourcing space
The impact of a CEO who loves to work

Molecule to Market: Inside the outsourcing space

Play Episode Listen Later Jun 20, 2025 50:29


In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Jeanne Taylor Hecht, Chief Executive Officer and Chairwoman at Lexitas. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jeanne, covering: How Jeanne's various roles have equipped her to become a more rounded CEO and board member. How a stint in Asia led Jeanne to develop her strategy playbook, including the importance of the client's voice. Jeanne's journey, taking on eight different boards and becoming a serial investor and advisor... and how that did not happen by accident. She said that having a strong relationship with a PE firm and missing the hands-on, day-to-day role of being a CEO led her back to the hot seat. Understanding why has being a specialist ophthalmology CRO given Lexitas traction with small to medium biotechs, and what is the future in store for CROS? Jeanne's industry career spanned over twenty-five years as a Board member and Chief Executive Officer of multiple companies, including CEO at Ora and Senior Executive at Median Technologies, IQVIA, Decision Biomarkers, and the UNC Oncology Protocol Office. Jeanne also launched and expanded a Life Sciences consulting practice that supported companies with sales, marketing, and market growth strategies and advisory and board work. She is primarily motivated by helping to bring relief to patients.  Jeanne is an active Advisory Board Member for the University of North Carolina Chapel Hill Kenan-Flagler's Business School and Lecturer at the business school. She contributed to the creation of Wake Forest University's master's in clinical research program and remains an active industry advisor to the school. She holds a Bachelor of Science from the University of Michigan and a Master of Business Administration from the university's Ross School of Business. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!  Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Dark Rhino Security Podcast
S17 E06 (VIDEO) Disaster Recovery Isn't Optional

Dark Rhino Security Podcast

Play Episode Listen Later Jun 19, 2025 45:51


Santosh Kaveti is the CEO and Founder of ProArch. He has over 18 years of experience as a technologist, entrepreneur, investor, and advisor. Santosh's vision and leadership have propelled ProArch to become a dominant force in key industry verticals, such as Energy, Healthcare & Lifesciences, and Manufacturing, where he leverages his expertise in manufacturing process improvement, mentoring, and consulting00:00 Intro03:48 Protect what matters the most12:32 Talking to the client. What is worth protecting24:27 Proarch29:30 The Cultural fit with acquisition 36:40 Disaster Recovery39:50 What do you think AI is going to do?43:55 Im too small to get attacked--------------------------------------------------------------To learn more about Santosh visit https://www.linkedin.com/in/santoshkaveti/To learn more about Dark Rhiino Security visit https://www.darkrhiinosecurity.com--------------------------------------------------------------

Dark Rhino Security Podcast
S17 E06 Disaster Recovery Isn't Optional

Dark Rhino Security Podcast

Play Episode Listen Later Jun 19, 2025 45:51


Santosh Kaveti is the CEO and Founder of ProArch. He has over 18 years of experience as a technologist, entrepreneur, investor, and advisor. Santosh's vision and leadership have propelled ProArch to become a dominant force in key industry verticals, such as Energy, Healthcare & Lifesciences, and Manufacturing, where he leverages his expertise in manufacturing process improvement, mentoring, and consulting00:00 Intro03:48 Protect what matters the most12:32 Talking to the client. What is worth protecting24:27 Proarch29:30 The Cultural fit with acquisition 36:40 Disaster Recovery39:50 What do you think AI is going to do?43:55 Im too small to get attacked--------------------------------------------------------------To learn more about Santosh visit https://www.linkedin.com/in/santoshkaveti/To learn more about Dark Rhiino Security visit https://www.darkrhiinosecurity.com--------------------------------------------------------------

Maiden Mother Matriarch with Louise Perry
The Evolution of Mental Illness - Marco Del Giudice | Maiden Mother Matriarch Episode 149

Maiden Mother Matriarch with Louise Perry

Play Episode Listen Later Jun 18, 2025 57:06


This is a free preview of a paid episode. To hear more, visit www.louiseperry.co.ukMy guest today is Marco Del Giudice, Associate Professor in the Department of Life Sciences at the University of Trieste. We spoke about one of Marco's key research interests: evolutionary psychopathology. That is, how our evolutionary history influences mental illness. We spoke about how gender differences in personality influence psychopathology, part…

Artificial Intelligence in Industry with Daniel Faggella
Building AI Systems That Think Like Scientists in Life Sciences - Annabel Romero of Deloitte

Artificial Intelligence in Industry with Daniel Faggella

Play Episode Listen Later Jun 18, 2025 31:01


Today's guest is Annabel Romero, Specialist Leader focusing on AI for Drug Discovery at Deloitte and a structural biologist by training. Deloitte is a global consulting firm known for its work in digital transformation, data strategy, and AI adoption across regulated industries. Annabel joins Emerj Editorial Director Matthew DeMello to explore how AI systems are being designed to think more like scientists—particularly in protein modeling and life sciences research. She shares how tools like AlphaFold and large language models are accelerating drug targeting, predicting allergen cross-reactivity, and translating learnings from human biology to agricultural innovation. This episode is sponsored by Deloitte. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

Tiny Matters
[BONUS] The FDA's ban of Red Dye No. 3 and the surprising science of winter roads: Tiny Show and Tell Us #25

Tiny Matters

Play Episode Listen Later Jun 18, 2025 17:03


In this episode of Tiny Show and Tell Us, we talk about why the FDA recently banned Red Dye No. 3 and how concerned people should be about its use in food. Then we cover icy winter roads and the fascinating science behind clearing them and taking a more sustainable approach that won't hurt the environment.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr Leadership
DR Leadership Lounge with Keith Willis of Core Management Training

Dr Leadership

Play Episode Listen Later Jun 18, 2025 50:01


Keith Willis joins the Lounge to discuss his early years of Military Service as an officer in the Gulf War and how it launched him into his Leadership journey. Founder of Core Management Training Keith gives great insight on the core competencies of Leadership.

Vital Health Podcast
Strengthening Biotech Ecosystems: Steve Potts & Robert Coughlin

Vital Health Podcast

Play Episode Listen Later Jun 18, 2025 44:01


In this Vital Health Podcast episode, host Duane Schulthess sits down with Steve Potts, biopharma entrepreneur and chair of the Drug Development Council (ICAN), and Robert Coughlin, Managing Director of Life Sciences at Jones Lang LaSalle, to explore how recent policy changes are reshaping the future of drug development. They unpack the unintended consequences of exclusivity gaps, discuss legislative fixes, and examine the broader impact on patients, investors, and regional biotech clusters. Key Topics:- Pill Penalty Explained: How nine-year data exclusivity for small molecules versus 13 years for biologics discourages investment in affordable therapies for older adults. - EPIC Act Solutions: A bipartisan proposal to extend small-molecule exclusivity to 13 years and rebalance research and development incentives. - Orphan Drug Incentives: Proposed reforms that would allow multiple exclusivity periods per drug to drive rare disease innovation. - Patient Advocacy Role: Strategies for empowering patients and disease foundations to influence policy and protect future therapies. - Biotech Ecosystem Impact: The effect of policy shifts on venture capital flows, lab space demand, and the health of regional innovation hubs. This episode highlights the critical link between policy design and the pace of medical innovation and why targeted legislative adjustments are essential to sustain future cures. It is a must-listen for policymakers, industry leaders, patient advocates, and anyone interested in the intersection of health policy and drug development. Recorded on May 30th, 2025.See omnystudio.com/listener for privacy information.

OffScrip with Matthew Zachary
Pediatric Engineering for the Rest of Us: Dr. Jamie Wells

OffScrip with Matthew Zachary

Play Episode Listen Later Jun 17, 2025 39:48


Dr. Jamie Wells is back—and this time, she brought a book. We cover everything from biomedical design screwups to the glorified billing software known as the EHR. Jamie's new book, A Clinical Lens on Pediatric Engineering, is a masterclass in what happens when you stop treating kids like small, drunk adults and start designing medicine around actual human factors. We talk about AI in pediatric radiology, why drug repurposing might save lives faster than biotech IPOs, and the absurdity of thinking one-size-fits-all in healthcare still works.Jamie's a former physician, a health policy disruptor, a bioethicist, an MIT director, and a recovering adjunct professor. She's also a unicorn. We dig into the wonk, throw shade at bad design, and channel our inner Lisa Simpsons. This one's for anyone who ever wondered why kids' hospitals feel like hell and why “make it taste like bubblegum” might be the most important clinical innovation of all time. You'll laugh, you'll learn, and you might get angry enough to fix something.RELATED LINKSJamie Wells on LinkedInBook: A Clinical Lens on Pediatric Engineering (Amazon)Book on SpringerDrexel BioMed ProfileGlobal Blockchain Business CouncilJamie's HuffPost ArticlesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Artificial Intelligence in Industry with Daniel Faggella
Challenges Slowing AI Adoption in Life Sciences Manufacturing - with Yunke Xiang of Sanofi

Artificial Intelligence in Industry with Daniel Faggella

Play Episode Listen Later Jun 17, 2025 20:11


Today's guest is Yunke Xiang, Global Head of Data Science for Manufacturing, Supply Chain, and Quality at Sanofi. Yunke joins Emerj Editorial Director Matthew DeMello to discuss the challenges that slow AI adoption in life sciences manufacturing, highlighting how fragmented data systems and legacy infrastructure create hurdles for AI initiatives. In this episode, Yunke explains how years of acquisitions and siloed data have made building a cohesive data foundation difficult, impacting AI's potential in manufacturing and supply chain optimization. Yunke shares Sanofi's approach to balancing build versus buy decisions for AI solutions and the critical role leadership plays in fostering an environment where data science can thrive. Yunke also reflects on the evolving landscape of AI in pharma manufacturing and the importance of strong governance and collaboration for successful implementation. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast! Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

How To Academy
Daniel Davis - The Real Science of Immune Health

How To Academy

Play Episode Listen Later Jun 17, 2025 69:46


We are surrounded by bold claims and quick fixes for ‘boosting' our immune health. But one thing the science is clear on is that everyone's immune system is unique – what is good for one person may not work well for another. So how do we separate the bogus claims from the useful advice? Head of Life Sciences and Professor of Immunology at Imperial College, Daniel Davis, helps us sort the facts from the fiction. From the genetics of immune health to the myth of Vitamin C, from evidence-backed studies on chronic stress to the gaps in knowledge on sleep and microbiome health, Daniel reveals what scientists do know for certain—and what still needs more answers—to help us make informed choices for ourselves. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Psychedelics Today
PT 606 - Ibogaine and the Future of Healing: Trevor Millar & Jonathan Dickinson of Ambio Life Sciences

Psychedelics Today

Play Episode Listen Later Jun 16, 2025 67:41


n this episode of Psychedelics Today, kicking of Psychedelic Science 2025 week in Denver, we sit down with Jonathan Dicksinson, Chief Executive Officer, and Trevor Millar, Chief Operations Officer of Ambio Life Sciences – one of the world's leading ibogaine clinics – to explore the potential of ibogaine for addiction, neuroregeneration, and how ethics, honoring experience, and sustainability will be key to delivering ibogaine at scale.  Trevor shares his early work supporting marginalized populations in Vancouver's Downtown Eastside, which led to the founding of Liberty Root, one of Canada's first ibogaine clinics. Jonathan reflects on his apprenticeship in Mexican clinics, years of international advocacy with the Global Ibogaine Therapy Alliance, and drafting the first set of clinical guidelines for ibogaine detoxification. Together with paramedic and ibogaine safety protocols expert Jose Inzunza, they co-founded Ambio in Tijuana in 2021. They discuss: The unique safety standards Ambio has pioneered – including industry-wide clinical protocols and magnesium therapy to mitigate cardiac risk. Their scale: over 3,000 patients treated, with 100+ clients per month across five dedicated houses in Baja California. Ambio's groundbreaking neuroregenerative program for Parkinson's, MS, and traumatic brain injury – which has already drawn patients like Brett Favre and Clay Walker. How ibogaine appears to drive profound physiological change – including evidence of TBI reversal as shown in Stanford's 2024 study on Special Forces veterans. Why ibogaine isn't just a molecule – it opens a long-lasting “critical period” of neuroplasticity that must be supported with preparation, integration, and holistic care. The deeper story of sourcing: through his company Terragnosis, Jonathan is the only person with a legal export license for Tabernanthe iboga from Gabon, and Ambio is setting a precedent for reciprocal and ethical global supply chains. Their cautionary perspective on Texas' $50M push toward ibogaine clinical trials – and why the traditional “one drug, one indication” model misses the complexity and promise of psychedelic healing. They also make a compelling case that Ambio is already modeling what the future of psychedelic care should look like – not a single drug in a sterile clinical setting, but a comprehensive, integrated protocol combining preparation, medical oversight, and deep integration. “Start with the end in mind,” Trevor urges – Ambio isn't just part of the movement; it's the blueprint for how ibogaine could be delivered worldwide. Links: Ambio Website: https://ambio.life/ Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis (Frontiers in Immunology, Feb 2025) Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Nature Medicine, Jan 2024) Ibogaine reduced severe neuropathic pain associated with a case of brachial plexus nerve root avulsion (Frontiers in Pain Research, Aug 2023) Novel treatment of opioid use disorder using ibogaine and iboga in two adults (Journal of Psychedelic Studies, Jan 2020) Clinical Guidelines for Ibogaine-Assisted Detoxification Ambio Life Sciences Launches World's First Clinical Ibogaine Program for Patients With Neurodegenerative Conditions Bios:  Jonathan Dickinson is the Chief Executive Officer and Co-Founder of Ambio Life Sciences. One of the world's leading experts on ibogaine, Jonathan brings over 15 years of experience in clinical care, traditional practice, and psychedelic research to his leadership at Ambio. A Mexico-licensed psychologist and former Executive Director of the Global Ibogaine Therapy Alliance, he authored the field's foundational safety guidelines and has published widely on ibogaine's therapeutic, cultural, and ecological significance. He holds the only active export license for Tabernanthe iboga root, led the first Nagoya-compliant export from Gabon, and was initiated into the Dissoumba/Fang tradition of Bwiti in 2014 and the Missoko tradition in 2022. He has co-authored peer-reviewed research on ibogaine's potential for trauma, TBI, pain, MS, and Parkinson's. At Ambio, he leads strategy, research, and innovation – advancing a globally scalable model of care that bridges tradition, science, and integrity. Trevor Millar is the Chief Operating Officer and Co-Founder of Ambio Life Sciences. A social entrepreneur and pioneer in ibogaine advocacy and treatment, Trevor brings over a decade of experience supporting individuals through addiction recovery, trauma healing, and post-treatment integration. His background includes co-founding the Canadian Psychedelic Association and serving as Chair of the Board for MAPS Canada. He has co-authored peer-reviewed research on ibogaine's applications for trauma, TBI, and opioid use disorder, and has been featured in award-winning documentaries including DOSED and In Waves and War. Grounded in personal experience and guided by a philosophical approach to healing, Trevor is helping shape a new model for ethical, integrative psychedelic care on a global scale. At Ambio, Trevor leads operations, strategic partnerships, and client experience – bridging clinical care with systems design, education, and public advocacy.

Business Of Biotech
Proactive Procurement Strategies For Biotech With Tom Wells

Business Of Biotech

Play Episode Listen Later Jun 16, 2025 58:23 Transcription Available


We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Tom Wells, Director of Life Sciences at 4C Associates, reveals why -- and how -- smart procurement practices can make or break emerging biotech companies during critical growth stages. Tom shares insights into procurement tools and strategies that can deliver breakthrough solutions, how poor procurement practices can damage investor confidence, and why thinking about procurement as the front end of demand flow, not the back end of supply chain, can help drug developers avoid costly mistakes. This episode of the Business of Biotech is brought to you by Ecolab. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Project Medtech
Episode 223 | Harrison Lands, Director, Translational Sciences at UPMC Enterprises | Investing in Innovation: Inside UPMC's Payer/Provider Model & Life Science Strategy

Project Medtech

Play Episode Listen Later Jun 16, 2025 30:23


In this episode, Duane Mancini is joined by Harrison Lands, Director of Translational Sciences at UPMC Enterprises. Harrison brings a unique perspective, shaped by his background as a physician, MBA, consultant, and now investor. We delve into the workings of UPMC Enterprises, exploring their investment thesis – the who, what, how much, when, and how their fund operates. Harrison also sheds light on the powerful advantages of UPMC's payer/provider integrated medical system and its impact on fostering innovation. The conversation touches on the vibrant Pittsburgh life science community, Harrison's time at the University of Virginia, and insights from CvilleBioHub. Tune in to understand how a major integrated health system strategically invests and drives translational science forward.Harrison Lands LinkedInUPMC Enterprises WebsiteDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedIn

三腳貓實驗室 Tripod Cat's Great Adventure - Presented by MTBA
Happy Hour 017:睽違半年回歸!全球首創客製化基因療法!近期研討會回顧

三腳貓實驗室 Tripod Cat's Great Adventure - Presented by MTBA

Play Episode Listen Later Jun 16, 2025 74:34


睽違半年Happy Hour總算更新啦!這次若晴跟Angel來聊聊最近剛從研討會回來的一些見聞和心得,非常適合搭配上一集新手村005一起收聽!當然我們也不忘Happy Hour的慣例,跟大家分享了一則近期非常振奮人心的客製化基因療法突破的新聞。等待Happy Hour已久的聽眾趕緊收聽吧! 節目內容: 跟大家更新一下近況 客製化基因療法大突破 芝加哥三腳貓4/6小聚 AACR開幕式小花絮 跟同事學了poster session的搜集資訊的招數 小廢物拿好拿滿還有免費專業大頭照 NIH fellowship小會議見聞 會議結識新朋友的喜悅 -- Hosting provided by SoundOn

Choses à Savoir
Pourquoi le "paradoxe français" a dopé les ventes de vin ?

Choses à Savoir

Play Episode Listen Later Jun 16, 2025 3:04


Le "paradoxe français" désigne une observation intrigante : les Français, malgré une alimentation riche en graisses saturées (fromages, beurre, charcuterie), ont un taux relativement bas de maladies cardiovasculaires, en comparaison avec d'autres pays occidentaux comme les États-Unis. Cette contradiction apparente a été mise sous les projecteurs aux États-Unis le 17 novembre 1991, lors d'un épisode de l'émission très populaire 60 Minutes diffusée sur CBS. Le segment, intitulé "The French Paradox", présentait l'idée que la consommation régulière de vin rouge par les Français pourrait être la clé de leur bonne santé cardiovasculaire.L'impact de cette émission a été immédiat : selon les données du Wine Market Council, les ventes de vin rouge ont augmenté de 44 % aux États-Unis dans les mois qui ont suivi. En 1992, le vin rouge représentait environ 70 % des nouvelles ventes de vin sur le marché américain, contre seulement 50 % l'année précédente. Certaines marques françaises comme Château Lafite Rothschild ont vu leur popularité exploser, et les importations de vin français ont fortement progressé.Sur le plan scientifique, l'un des principaux promoteurs de ce concept était le chercheur Serge Renaud de l'INSERM à Lyon. Dans un article publié en 1992 dans The Lancet, il avance que la consommation modérée de vin rouge – un à deux verres par jour – pourrait réduire le risque de maladies coronariennes de 40 %. Le vin rouge contient en effet des polyphénols, dont le plus connu est le resvératrol, un antioxydant présent dans la peau du raisin. Des études comme celle de J.P. Fremont (1999, Life Sciences) ont suggéré que le resvératrol inhibe l'agrégation des plaquettes et protège les vaisseaux sanguins.Le "paradoxe français" est alors devenu un argument marketing massif. L'industrie vinicole, en France comme aux États-Unis, s'en est emparée pour promouvoir le vin rouge comme un produit "santé". Cette stratégie a contribué à modifier l'image du vin outre-Atlantique, le faisant passer d'un produit de luxe européen à un choix de consommation perçu comme bénéfique.Cependant, cette idée a été nuancée fortement depuis. Aujourd'hui on sait que scientifiquement, la consommation modérée d'alcool n'est pas totalement sans risque, même à faibles doses.Citons l'étude de référence : The Lancet, 2018 – Global Burden of Disease StudyIl s'agit de l'une des études les plus vastes jamais réalisées sur le sujet, couvrant plus de 28 millions de personnes dans 195 pays. Elle conclut que le niveau de consommation d'alcool le plus sûr est zéro. Même à faibles doses, l'alcool augmente les risques de certains cancers, de maladies cardiovasculaires et de blessures.Cette étude remet donc totalement en cause l'idée selon laquelle une consommation modérée, comme un verre de vin par jour, pourrait être bénéfique pour la santé. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Finding Genius Podcast
AI Breakthroughs, AGI Risks, & The Future Of Thought: A Conversation With Dr. Bo Wen

Finding Genius Podcast

Play Episode Listen Later Jun 14, 2025 46:40


Meet Dr. Bo Wen, a staff research scientist, AGI specialist, cloud architect, and tech lead in digital health at IBM. He's joining us to discuss his perspective on the rapid evolution of AI – and what it could mean for the future of human communication… With deep expertise in generative AI, human-AI interaction design, data orchestration, and computational analysis, Dr. Wen is pushing the boundaries of how we understand and apply large language models. His interdisciplinary background blends digital health, cognitive science, computational psychiatry, and physics, offering a rare and powerful lens on emerging AI systems. Since joining IBM in 2016, Dr. Wen has played a key role in the company's Healthcare and Life Sciences division, contributing to innovative projects involving wearables, IoT, and AI-driven health solutions. Prior to IBM, he earned his Ph.D. in Physics from the City University of New York and enjoyed a successful career as an experimental physicist. In this conversation, we explore: How Dr. Wen foresaw the AI breakthrough nearly a decade ago The implications of AGI for communication, reasoning, and human-AI collaboration How large language models work. What AI needs to understand to predict words in sentences.  Want to dive deeper into Dr. Wen's work? Learn more here! Episode also available on Apple Podcasts: http://apple.co/30PvU9C

HealthcareNOW Radio - Insights and Discussion on Healthcare, Healthcare Information Technology and More
Digital Health Talks: Breaking Free from Healthcare's Escape Room

HealthcareNOW Radio - Insights and Discussion on Healthcare, Healthcare Information Technology and More

Play Episode Listen Later Jun 13, 2025 28:04


Breaking Free from Healthcare's Escape Room: Tom Lawry on AI Strategy and Systemic Hope Tom Lawry, Microsoft's former Director for AI in Health and Life Sciences and author of the new book Health Care Nation, joins us to discuss moving beyond healthcare fatalism toward actionable reform. Named one of 20 people transforming healthcare through practical AI applications, Lawry reveals how leaders can escape the industry's design flaws through strategic technology deployment and "micro-dosing hope." Essential listening for executives ready to move from critique to implementation. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Accenture AI Leaders Podcast
AI Leaders Podcast #73: AI in MedTech: Enabling the Future of Care

Accenture AI Leaders Podcast

Play Episode Listen Later Jun 13, 2025 43:12


In this thoughtful conversation, we explore the transformative role of AI in healthcare. From over a thousand FDA-approved AI-enabled medical devices to breakthroughs in medical imaging, the discussion highlights the importance of trust, transparency, and bias mitigation. Join Tracy Ring, Chief Data Officer and Global Generative AI Lead for Life Sciences; Tom Kawalec, Managing Director for Life Sciences Practice at Accenture; and Shaye Mandle, Executive Director of Digital Health Tech at AdvaMed, as they delve into AI's future in personalized care and its potential to reduce healthcare costs.

Life Science Success
Navigating Biotech Risks: Insider's Playbook for Success

Life Science Success

Play Episode Listen Later Jun 13, 2025 34:56


Send us a textDaniel Tabb brings over 15 years of experience in the insurance industry, specializing in working with Life Science companies ranging from pre-seed startups to publicly traded corporations. As a leader of the Life Science Practice at Houchens Insurance Group, Daniel possesses a deep understanding of the unique risks and challenges faced by life science companies in today's dynamic environment.00:00 Introduction to Life Science Success Podcast00:29 Meet Daniel Tabb: Life Sciences Insurance Expert01:26 Daniel's Journey into the Insurance Industry03:32 Specializing in Life Sciences05:09 Key Career Transition Points12:06 Understanding Life Sciences Insurance15:49 Unique Risks and Challenges in Life Sciences18:23 Innovative Projects and Future of Insurance24:17 Leadership and Personal Insights33:49 Conclusion and Final Thoughts

Life Science Success
Breakthrough Marketing Secrets for Life Science Companies

Life Science Success

Play Episode Listen Later Jun 13, 2025 55:57


Send us a textIn this episode of the Life Science Success Podcast my guest is Holley Miller, a category designer and commercial growth expert who helps life sciences companies drive reliable revenue and build market dominance through her innovative strategies at Grey Matter Marketing. With 30 years of experience in global marketing and product management, Holley transforms companies by changing market behaviors and creating category leadership.00:00 Introduction to Life Science Success Podcast00:35 Meet Holley Miller: Category Designer and Commercial Growth Expert01:35 Holley's Journey into Life Sciences02:41 Transition from Tobacco to Medical Devices05:15 Understanding Category Design08:58 Examples of Successful Category Design12:05 Founding Grey Matter Marketing18:04 Challenges in Life Sciences Marketing23:14 Strategies for Effective Market Adoption26:46 The Importance of Problem Marketing29:12 Innovative Solutions in Spinal Surgery31:33 Frameworks for Understanding Company Vision35:17 Challenges and Overcoming Obstacles37:53 Evolution and Lessons from Grey Matter40:35 Focus Areas and Client Selection43:27 Success Stories and Impact47:29 Leadership Advice and Inspirations48:44 Concerns and Future of Healthcare Technology50:12 Generative AI and Future Prospects54:25 Conclusion and Contact Information

Taking the Pulse: a Health Care Podcast
Episode 238: Navigating IP and AI in Life Sciences with Bryan Baysinger of Maynard Nexsen:

Taking the Pulse: a Health Care Podcast

Play Episode Listen Later Jun 12, 2025 20:05


This week, Heather and Matthew are joined by their colleague Bryan Baysinger, Maynard Nexsen attorney and leader of the firm's Intellectual Property practice group. We dive into the evolving challenges life sciences companies face in protecting intellectual property in a time when artificial intelligence is reshaping research and innovation. From securing patents and trade secrets to navigating international competition, Bryan offers practical guidance for companies looking to strengthen their IP portfolios. Tune in for insights on the intersection of IP, AI, and the future of the life sciences industry

OffScrip with Matthew Zachary
Pinky Swear: Erica Campbell and The Wanted Mastectomy

OffScrip with Matthew Zachary

Play Episode Listen Later Jun 10, 2025 40:59


Erica Campbell walked away from corporate life, took a hard left from the British Embassy, and found her calling writing checks for families nobody else sees. As Executive Director of Pinky Swear Foundation, she doesn't waste time on fluff. Her team pays rent, fills gas tanks, and gives sick kids' parents the one thing they don't have—time. Then, breast cancer hit her. She became the patient. Wrote a book about it. Didn't sugarcoat a damn thing. We talk about parking fees, grief, nonprofit burnout, and how the hell you decide which families get help and which don't. Also: AOL handles, John Hughes, and letters from strangers that make you cry. Erica is part Punky Brewster, part Rosie the Robot, and part Lisa Simpson—with just enough GenX Long Island sarcasm to make it all land. This one sticks.RELATED LINKSPinky Swear FoundationThe Mastectomy I Always Wanted (Book)Erica on LinkedInThink & Link: Erica Campbell“Like the Tale of a Starfish” - Blog Post“Cancer Diagnosis, Messy Life, Financial Support” - Blog PostFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Conversation Weekly
The 15% solution part 1: why global tax reform is long overdue

The Conversation Weekly

Play Episode Listen Later Jun 5, 2025 26:10


For decades, multinational corporations have used sophisticated strategies to shift profits away from where they do business. As a result, countries around the world lose an estimated US$500 billion annually in unpaid taxes, with developing nations hit particularly hard.In the first episode of The 15% solution, we explore how companies have exploited loopholes in the global tax system. We speak to Annette Alstadsæter, director of the Centre for Tax Research at the Norwegian University of Life Sciences, and Tarcisio Diniz Magalhaes, a professor of tax law at the University of Antwerp in Belgium. In 2021, after years of international negotiations, the Organisation for Economic Co-operation and Development unveiled a global tax deal designed to address tax avoidance through a minimum corporate tax rate of 15%. But will this new framework actually work? And what happens when major economies refuse to participate? The 15% solution explores why a new global tax regime is needed, whether it can fix a broken system, and what's at stake if it fails.This episode of The Conversation Weekly was written and produced by Mend Mariwany. Gemma Ware is the executive producer. Mixing and sound design by Eloise Stevens and theme music by Neeta Sarl. Sound design and mixing by Eloise Stevens and theme music by Neeta Sarl. Read the full credits for this episode and sign up here for a free daily newsletter from The Conversation.If you like the show, please consider donating to The Conversation, an independent, not-for-profit news organisation. Donation

OffScrip with Matthew Zachary
Dr. Allyson Ocean Unfiltered: Science, Colons and Calling BS

OffScrip with Matthew Zachary

Play Episode Listen Later Jun 3, 2025 43:38


Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

OffScrip with Matthew Zachary
[BONUS] No One Told Me: COVID and Cancer

OffScrip with Matthew Zachary

Play Episode Listen Later May 30, 2025 4:48


Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.